Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,418 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluid administration Clear all

Conditions: Bladder Cancer
Interventions: Docetaxel, ZD1839, Dexamethasone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Retinal Detachment, Full Thickness Macular Hole, Epiretinal Membrane
Interventions: Pars plana vitrectomy, External drainage; Procedure
Lead sponsor: Allen C. Ho, MD; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions: Not listed
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 6,086 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metastatic Breast Cancer
Interventions: Epicutaneous cryoimmunotherapy, Topical imiquimod, Pembrolizumab, Dermatologic Quality of Life Index, Functional Assessment of Cancer Therapy, Intra-lesional GM-CSF, Cry-AC, Cutaneous tumor biopsy, Peripheral blood draw for research; Device · Drug · Other + 1 more
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obesity
Interventions: group sessions, sibutramine, orlistat, diethylpropion, Low Calorie Diet, Health One, Intensive Medical Combination Therapy for Obesity, Control Condition; Behavioral · Drug · Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years to 60 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Blood Draw, Lumbar Puncture; Procedure
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: COVID-19 Pneumonia, Impaired Respiratory Function
Interventions: MAS825, Placebo, Standard of Care (SoC); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 21
States / cities: Chula Vista, California • Glendale, California • Irvine, California + 17 more

Conditions: Atopic Dermatitis, Eczema
Interventions: Pre-Treatment with Dial liquid antibacterial soap, Control; Drug · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy Volunteer
Interventions: [14C]-EDG-7500; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: raltegravir; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetic Ketoacidosis
Interventions: Two bag system; Other
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Decision Support System, Outcome
Interventions: Routine care, AFM; Procedure · Device
Lead sponsor: Assistance Publique - Hôpitaux de Paris; Other
Eligibility: 18 Years and older
Enrollment: 2,007 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Irvine, California • Los Angeles, California

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Helminth ova; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Migraine Disorders
Interventions: Middle Meningeal Artery embolization; Device
Lead sponsor: Cerenovus, Part of DePuy Synthes Products, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Walnut Creek, California • Hartford, Connecticut • Buffalo, New York + 5 more

Conditions: Colorectal Cancer, Healthy, no Evidence of Disease, Precancerous Condition
Interventions: gene expression analysis, polymerase chain reaction, polymorphism analysis, protein expression analysis, proteomic profiling, gas chromatography, laboratory biomarker analysis, liquid chromatography, mass spectrometry, questionnaire administration; Genetic · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Rotavirus Infection, Rotavirus Vaccines
Interventions: Rotarix, Pediarix, Hiberix, Prevenar 13; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 1,280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 47
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more

Conditions: Pleural Effusion
Interventions: Automatic Continuous Effusion Shunt implantation; Device
Lead sponsor: Pleural Dynamics, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Hollywood, Florida • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more

Conditions: Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS)
Interventions: HDM201, MBG453, Venetoclax; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Asthma
Interventions: QGE031, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Birmingham, Alabama • Kingwood, Texas • Plano, Texas

Conditions: Ascites, Cirrhosis
Interventions: Residency Program Teaching, Lecture, Pocket Card Reference, Pager; Behavioral · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: Not listed
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Kidney Injury
Interventions: 0.9% Normal Saline (0.9% Sodium Chloride) injection, Isolyte S injection; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Foscarnet sodium; Drug
Lead sponsor: Astra USA; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 11
States / cities: Beverly Hills, California • Los Angeles, California • Redwood City, California + 7 more

Conditions: Obesity
Interventions: Fed Condition, Fasted Condition; Procedure
Lead sponsor: New York Obesity and Nutrition Research Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: New York, New York

Conditions: Glomerulosclerosis, Focal
Interventions: Cyclosporin, Mycophenolate mofetil and Dexamethasone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years to 40 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer

Inflammasomes in Cell Death in FTMH, ERM, and RRD

A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer

LOSS- Louisiana Obese Subjects Study

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

Study of Efficacy and Safety of MAS825 in Patients With COVID-19

Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival

A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500

Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients

Two Bag System for Diabetic Ketoacidosis

Assisted Fluid Management (AFM) System and Postoperative Outcome After High-risk Abdominal Surgery

Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis

MMA Embolization for Refractory Chronic Migraine

Study of Biomarkers in Blood & Tissue Samples From Patients With Colorectal Cancer or Polyps & Patients Without Polyps

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

The ACES Study for Aseptic Pleural Effusion

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma

Improving Performance of Paracentesis in Medical Residency Training

Fluid Chloride and AKI in Cardiopulmonary Bypass

A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)

Brain Activation in Response to Appetitive Cues Pre- and Post- Bariatric Surgery

Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)